Skip to content
Menu

Lisata Therapeutics, Inc. LSTA

Full chart Compare
Set alert

Price alert · LSTA

All alert types
1.21 USD -0.07 (-5.47%)

Regular-session close

1.15 -0.06 -4.96%

After hours · Nov 13, 4:00 PM ET

1.20 Day range 1.26
0.96 52-week range 5.07
YTD
-34.95%
1 year
-41.55%
Market cap
13.07M
EPS (ttm)
-1.64
Shares out
8.39M
Forward P/E
-1.20
YTD return
-34.95%
1-year return
-41.55%
Volume
104.86K
Avg volume
304.42K
Open
1.25
Previous close
1.28
Day's range
1.20 – 1.26
52-week range
0.96 – 5.07
Beta
1.22
Analysts
Strong Buy
Price target
14.00 (+1057.0%)

 

No chart data for this range yet.

Key statistics

Enterprise value
-15.08M
PEG ratio
0.00
Price / sales
0.00
Price / book
0.51
Dividend yield
0.00%
Payout ratio
0.00%
Revenue growth
0.00%
Free cash flow
-13.25M
Total cash
38.26M
Total debt
223.00K
Return on equity
-44.03%
Short % of float
0.25%
50-day average
2.82
200-day average
3.03

Fundamental scorecard

6 of 25 checks passed on LSTA’s reported financials

Value: 0/5ValueGrowth: 1/5GrowthProfitability: 0/5ProfitabilityFinancial health: 5/5HealthDividend: 0/5Dividend

6of 25 checks passed

  • Value 0 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 5 of 5
  • Dividend 0 of 5

Statements to Jun 30, 2026.

Financials — quick view

All financials
LSTA Revenue — quarterly 0
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
LSTA Net income — quarterly -2.93M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
LSTA EPS — quarterly -0.32
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

LSTA recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 12, 2024Sep 1, 2024-0.75-0.59+0.16+21.33%
Aug 12, 2024Jun 1, 2024-0.75-0.61+0.14+18.67%
May 9, 2024Mar 1, 2024-0.73-0.65+0.08+10.96%
Feb 29, 2024Dec 1, 2023-0.86-0.66+0.20+23.26%
Nov 2, 2023Sep 1, 2023-0.93-0.65+0.28+30.11%
Aug 14, 2023Jun 1, 2023-0.70-0.50+0.20+28.57%

Upgrades / downgrades

LSTA analyst upgrades and downgrades
DateFirmActionFromTo
Dec 11, 2024HC Wainwright & Co.reitBuyBuy
Nov 21, 2024HC Wainwright & Co.reitBuyBuy
Sep 18, 2024HC Wainwright & Co.reitBuyBuy
Aug 13, 2024HC Wainwright & Co.reitBuyBuy
Jul 19, 2024HC Wainwright & Co.reitBuyBuy
Jul 10, 2024HC Wainwright & Co.reitBuyBuy

About Lisata Therapeutics, Inc.

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
lisata.com

News

Your note

Sign in to keep a note on LSTA — it syncs with the Stock Master app.

Insider holders

LSTA insider holders
InsiderRelationLatest transactionDateShares held
AZAB MOHAMMADDirectorStock Award(Grant)Jan 8, 202458,680
BROWN GREGORY BDirectorStock Award(Grant)Jan 8, 202449,414
BUCK KRISTEN KOfficerStock Award(Grant)Sep 30, 202462,672
FLOWERS CYNTHIA LOUISEDirectorStock Award(Grant)Jan 8, 202449,201
HENSON HEIDIDirectorStock Award(Grant)Jan 8, 202439,480
KLOSK STEVEN MARKDirectorStock Award(Grant)Jan 8, 202449,570

Institution ownership

LSTA institution ownership
Holder% heldSharesValueReported
BML Capital Management, LLC3.39%284,669859.70KSep 29, 2024
Vanguard Group Inc2.22%186,366562.83KSep 29, 2024
Renaissance Technologies, LLC1.23%103,622312.94KSep 29, 2024
Blackrock Inc.0.67%56,013169.16KSep 29, 2024
Geode Capital Management, LLC0.66%55,681168.16KSep 29, 2024
Dimensional Fund Advisors LP0.21%17,34052.37KSep 29, 2024

Fund ownership

LSTA fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund1.52%127,737385.76KSep 29, 2024
Vanguard Extended Market Index Fund0.69%57,596173.94KSep 29, 2024
Fidelity Extended Market Index Fund0.47%39,405119.00KOct 30, 2024
Fidelity Series Total Market Index Fund0.07%5,46116.49KOct 30, 2024
Dimensional ETF Tr-Dimensional U.S. Equity ETF0.05%3,85111.63KJul 30, 2024
Fidelity Total Market Index Fund0.05%4,37913.22KOct 30, 2024